Ly Vu

Assistant Professor

  • Email: lyv@sfu.ca
  • Tel: (778) 782-7096
  • Office: SSB7142

  • Lab Website
  • Research Page
  • Lab: SSB 7138
  • Lab Tel: (778) 782-6811

Education

  • B.Sc. in Biology, College of Science - the Honor Program for Talented Students, Vietnam National University
  • Ph.D. in Cancer Biology, Memorial Sloan Kettering Cancer Center, USA

Research Interests

The overarching goal of our laboratory is to understand the control of stem cells in development and diseases. Our research is focused on uncovering novel mechanisms of post-transcriptional and translational regulation during normal and malignant hematopoiesis. We aim to develop innovative therapeutic approaches targeting these regulatory pathways in leukemia and in cancer.

While disruption of genetic and epigenetic mechanisms and altered signaling networks are commonly studied, the role post-transcriptional and translational regulation in tumorigenesis has only recently recognized. We are particularly interested in defining the regulation of mRNA decay and translation mediated by poly(A) tail length and RNA deadenylation complexes and other RNA binding proteins in the context of normal and leukemia stem cells. Despite the central role of mRNA decay and poly(A) tails in regulating and coupling RNA metabolism and translation, it is virtually unknown how these processes contribute to drive and maintain the self-renewal and oncogenic gene expression programs in stem cells and cancer. Our work will provide insights into this largely unexplored area and enable development of new therapies. The laboratory employs human and mouse models; a broad range of molecular biology methods and a global approach using next generation sequencing techniques to decipher regulation of gene expression at multiple layers from transcription to mRNA biogenesis and translation.

For more information, visit our research lab website.

Job Opportunities:

Research Assistant - Temporary full-time

Selected Publications

  • Vu LP, Cheng Y, Kharas MG. The Biology of m6A RNA Methylation in Normal and Malignant Hematopoiesis. Review. Cancer Discov. 2019 Jan;9(1):25-33. doi: 10.1158/2159-8290.CD-18-0959.
  • Vu LP*, Pickering BF*, Cheng Y*, Zaccara S, Nguyen D, Minuesa G, Chou T, Chow A, Saletore Y, MacKay M, Schulman J, Famulare C, Patel M, Klimek VM, Garrett-Bakelman FE, Melnick A, Carroll M, Mason CE, Jaffrey SR, Kharas MG. * authors contributed equally. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal and leukemia cells. Nature Medicine. 2017 Sep 18. doi: 10.1038/nm.4416. PMID: 28920958.
  • Vu LP, Prieto C, Amin E, Minuesa G, Chhangawala S, Vidal MJ, Krivtsov A, Chou T, Barlowe T, Taggart J, Tivnan P, Deering RP, Gonen M, Figueroa M, Paietta E, Tallman MS, Melnick A, Levine RL, Fatima Al-Shahrour, Järås M, Chu L, Garippa R, Lengner C, Armstrong SA, Cowley G, Root D, Doench JG, Cerchietti L, Leslie C, Ebert B, Kharas MG. MSI2 interactome screen reveals requirement for RNA binding protein SYNCRIP in myeloid leukemia stem cells.  Nature Genetic. 2017 Jun;49(6):866-875. doi: 10.1038/ng.3854.  PMID: 28436985.
  • Park SM, Gonen M, Vu L, Minusa G, Tivnan P, Barlowe TS, Taggart J, Lu Y, Deering RP, Hacohen N, Figueroa ME, Paietta E, Parnandez HF, Tallman MS, Melnick A, Levin R, Lesli C, Lengner CJ, Kharas MG.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Cli Invest. 2015 Mar 2; 125(2): 1286-98. doi: 10.1172/JCI78440. PMID: 25664853.
  • Vu LP, Perna F, Wang L, Voza F, Figueroa ME, Tempst P, Erdjument-Bromage H, Gao R, Chen S, Paietta E, Deblasio T, Melnick A, Liu Y, Zhao X, Nimer SD.  PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex.  Cell Rep. 2013 Dec 26;5(6):1625-38. doi: 10.1016/j.celrep.2013.11.025. PMID: 24332853

 

Courses

Future courses may be subject to change.